Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure

The Kyushu University Liver Disease Study (KULDS) Group

研究成果: ジャーナルへの寄稿記事

5 引用 (Scopus)

抄録

Favourable efficacy and safety profiles for simeprevir in combination with pegylated interferon alpha (PEG-IFNα) and ribavirin (triple therapy) have been shown in clinical trials. This study was carried out to evaluate the effectiveness of simeprevir-based triple therapy for patients with prior telaprevir treatment failure. This multicentre, observational cohort consisted of 345 consecutive Japanese patients infected with HCV genotype 1b, including 20 who had experienced telaprevir-based triple therapy. Amino acid substitutions in the NS3/4A region were identified by direct sequencing at the time of relapse or breakthrough in treatment with telaprevir and at the initiation of treatment with simeprevir. Patients were stratified according to prior response to PEG-IFNα and ribavirin. Of the 20 patients with telaprevir treatment failure, 10 (50.0%) achieved sustained virological response at week 12 after the end of treatment (SVR12). For patients treatment naïve [3/4 (75.0%)] or with prior relapse [1/1 (100%)] or partial response [5/6 (83.3%)] to PEG-IFNα and ribavirin, almost all achieved SVR12, mainly because of the improvement of treatment adherence, especially to direct-acting antiviral agent and ribavirin. However, of the nine patients with prior null response to PEG-IFNα and ribavirin, only one (11.1%) achieved SVR12, despite all having received an adequate treatment dosage, and five (55.6%) achieved rapid virological response. The treatment outcome of simeprevir-based triple therapy for HCV genotype 1b patients with prior telaprevir failure depended on the prior response to PEG-IFNα and ribavirin. For patients with prior null response to PEG-IFNα and ribavirin, retreatment with simeprevir-based triple therapy is not a useful option.

元の言語英語
ページ(範囲)992-1001
ページ数10
ジャーナルJournal of Viral Hepatitis
22
発行部数12
DOI
出版物ステータス出版済み - 12 1 2015

Fingerprint

Chronic Hepatitis C
Genotype
Ribavirin
Interferon-alpha
Therapeutics
Treatment Failure
Simeprevir
telaprevir
Recurrence
Retreatment
Amino Acid Substitution
Antiviral Agents
Clinical Trials
Safety

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases
  • Virology

これを引用

Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. / The Kyushu University Liver Disease Study (KULDS) Group.

:: Journal of Viral Hepatitis, 巻 22, 番号 12, 01.12.2015, p. 992-1001.

研究成果: ジャーナルへの寄稿記事

The Kyushu University Liver Disease Study (KULDS) Group. / Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. :: Journal of Viral Hepatitis. 2015 ; 巻 22, 番号 12. pp. 992-1001.
@article{238adf4be1134b3b93bdc5449119d609,
title = "Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure",
abstract = "Favourable efficacy and safety profiles for simeprevir in combination with pegylated interferon alpha (PEG-IFNα) and ribavirin (triple therapy) have been shown in clinical trials. This study was carried out to evaluate the effectiveness of simeprevir-based triple therapy for patients with prior telaprevir treatment failure. This multicentre, observational cohort consisted of 345 consecutive Japanese patients infected with HCV genotype 1b, including 20 who had experienced telaprevir-based triple therapy. Amino acid substitutions in the NS3/4A region were identified by direct sequencing at the time of relapse or breakthrough in treatment with telaprevir and at the initiation of treatment with simeprevir. Patients were stratified according to prior response to PEG-IFNα and ribavirin. Of the 20 patients with telaprevir treatment failure, 10 (50.0{\%}) achieved sustained virological response at week 12 after the end of treatment (SVR12). For patients treatment na{\"i}ve [3/4 (75.0{\%})] or with prior relapse [1/1 (100{\%})] or partial response [5/6 (83.3{\%})] to PEG-IFNα and ribavirin, almost all achieved SVR12, mainly because of the improvement of treatment adherence, especially to direct-acting antiviral agent and ribavirin. However, of the nine patients with prior null response to PEG-IFNα and ribavirin, only one (11.1{\%}) achieved SVR12, despite all having received an adequate treatment dosage, and five (55.6{\%}) achieved rapid virological response. The treatment outcome of simeprevir-based triple therapy for HCV genotype 1b patients with prior telaprevir failure depended on the prior response to PEG-IFNα and ribavirin. For patients with prior null response to PEG-IFNα and ribavirin, retreatment with simeprevir-based triple therapy is not a useful option.",
author = "{The Kyushu University Liver Disease Study (KULDS) Group} and Eiichi Ogawa and Norihiro Furusyo and K. Dohmen and E. Kajiwara and A. Kawano and H. Nomura and K. Takahashi and T. Satoh and K. Azuma and M. Nakamuta and T. Koyanagi and K. Kotoh and Shinji Shimoda and J. Hayashi",
year = "2015",
month = "12",
day = "1",
doi = "10.1111/jvh.12427",
language = "English",
volume = "22",
pages = "992--1001",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure

AU - The Kyushu University Liver Disease Study (KULDS) Group

AU - Ogawa, Eiichi

AU - Furusyo, Norihiro

AU - Dohmen, K.

AU - Kajiwara, E.

AU - Kawano, A.

AU - Nomura, H.

AU - Takahashi, K.

AU - Satoh, T.

AU - Azuma, K.

AU - Nakamuta, M.

AU - Koyanagi, T.

AU - Kotoh, K.

AU - Shimoda, Shinji

AU - Hayashi, J.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Favourable efficacy and safety profiles for simeprevir in combination with pegylated interferon alpha (PEG-IFNα) and ribavirin (triple therapy) have been shown in clinical trials. This study was carried out to evaluate the effectiveness of simeprevir-based triple therapy for patients with prior telaprevir treatment failure. This multicentre, observational cohort consisted of 345 consecutive Japanese patients infected with HCV genotype 1b, including 20 who had experienced telaprevir-based triple therapy. Amino acid substitutions in the NS3/4A region were identified by direct sequencing at the time of relapse or breakthrough in treatment with telaprevir and at the initiation of treatment with simeprevir. Patients were stratified according to prior response to PEG-IFNα and ribavirin. Of the 20 patients with telaprevir treatment failure, 10 (50.0%) achieved sustained virological response at week 12 after the end of treatment (SVR12). For patients treatment naïve [3/4 (75.0%)] or with prior relapse [1/1 (100%)] or partial response [5/6 (83.3%)] to PEG-IFNα and ribavirin, almost all achieved SVR12, mainly because of the improvement of treatment adherence, especially to direct-acting antiviral agent and ribavirin. However, of the nine patients with prior null response to PEG-IFNα and ribavirin, only one (11.1%) achieved SVR12, despite all having received an adequate treatment dosage, and five (55.6%) achieved rapid virological response. The treatment outcome of simeprevir-based triple therapy for HCV genotype 1b patients with prior telaprevir failure depended on the prior response to PEG-IFNα and ribavirin. For patients with prior null response to PEG-IFNα and ribavirin, retreatment with simeprevir-based triple therapy is not a useful option.

AB - Favourable efficacy and safety profiles for simeprevir in combination with pegylated interferon alpha (PEG-IFNα) and ribavirin (triple therapy) have been shown in clinical trials. This study was carried out to evaluate the effectiveness of simeprevir-based triple therapy for patients with prior telaprevir treatment failure. This multicentre, observational cohort consisted of 345 consecutive Japanese patients infected with HCV genotype 1b, including 20 who had experienced telaprevir-based triple therapy. Amino acid substitutions in the NS3/4A region were identified by direct sequencing at the time of relapse or breakthrough in treatment with telaprevir and at the initiation of treatment with simeprevir. Patients were stratified according to prior response to PEG-IFNα and ribavirin. Of the 20 patients with telaprevir treatment failure, 10 (50.0%) achieved sustained virological response at week 12 after the end of treatment (SVR12). For patients treatment naïve [3/4 (75.0%)] or with prior relapse [1/1 (100%)] or partial response [5/6 (83.3%)] to PEG-IFNα and ribavirin, almost all achieved SVR12, mainly because of the improvement of treatment adherence, especially to direct-acting antiviral agent and ribavirin. However, of the nine patients with prior null response to PEG-IFNα and ribavirin, only one (11.1%) achieved SVR12, despite all having received an adequate treatment dosage, and five (55.6%) achieved rapid virological response. The treatment outcome of simeprevir-based triple therapy for HCV genotype 1b patients with prior telaprevir failure depended on the prior response to PEG-IFNα and ribavirin. For patients with prior null response to PEG-IFNα and ribavirin, retreatment with simeprevir-based triple therapy is not a useful option.

UR - http://www.scopus.com/inward/record.url?scp=84945452043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945452043&partnerID=8YFLogxK

U2 - 10.1111/jvh.12427

DO - 10.1111/jvh.12427

M3 - Article

C2 - 26075320

AN - SCOPUS:84945452043

VL - 22

SP - 992

EP - 1001

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 12

ER -